Healthcare

Obesity giants will begin $80 bln M&A face-off

17 Dec 2024

Eli Lilly and Novo Nordisk will need to invest the war chests they are amassing from sales of weight-loss drugs. They could snap up rivals like Zealand Pharma, or forge into new areas, say by buying autoimmune player Argenx. Pressure to do deals raises the risk of overpaying.

Bausch + Lomb buyout gets blurry beyond $7 bln

13 Dec 2024

Private equity firm TPG is interested in the eye care company, whose parent’s $20 bln of debt makes it a willing seller. A new owner will struggle to find big costs to cut and to exit at a higher valuation multiple. Such constraints make it harder to see clear to a 20% return.

AstraZeneca lacks good medicine for Chinese limbo

13 Dec 2024

Executives at the $205 bln drugmaker have been detained by Beijing, hitting its shares. One way for CEO Pascal Soriot to ringfence China risk from the rest of AstraZeneca might be to list or spin off the unit. Yet that might just highlight fresh reasons to mark down the stock.

UnitedHealth tragedy opens deep healthcare wounds

5 Dec 2024

The murder of insurance boss Brian Thompson drew a slew of callous responses, including on a company Facebook post. Industry profit is rising in a nation spending double its peers on healthcare for worse outcomes. Policy ideas are weak, but political risk is amping up.

Drugmakers brace for US political side effects

5 Dec 2024

Donald Trump’s health agency nominee, Robert Kennedy, brings dangerous views on vaccines as well as skepticism about sky-high medicine prices. In this week’s Viewsroom, Breakingviews columnists discuss the impact on giants like Novo Nordisk and how other countries might react.

European pharma’s growth prescription: pivot to US

28 Nov 2024

Novartis, Novo Nordisk and regional rivals lost $86 bln in value over concerns about tariffs and other possible measures by President-elect Donald Trump. Stateside M&A and manufacturing moves could ease the pain and boost revenue. But hopping across the pond will mean paying up.

Brookfield has room to sweeten Spanish drug deal

20 Nov 2024

Grifols rejected a 6.5 billion euro offer from the Canadian firm and its founder family. That’s not surprising, given the offer is far from generous and the pharma company’s sales are recovering. Bruce Flatt’s group can afford to pay more and still clear an acceptable return.

Amcor’s cheap packaging deal hides a fragile item

20 Nov 2024

The Switzerland-based company is paying $8.4 bln for US rival Berry. It’s a low price when compared with the cost savings on offer, but the target brings with it debt and a business that is struggling to grow. Rapid consolidation among peers also raises the pressure to merge.

Vaccine makers exposed to political pathogen

7 Nov 2024

President-elect Donald Trump wants Robert Kennedy to ‘run wild’ on public health policy. Details, as usual, are sketchy, and it may be hard to put the anti-jab activist in an official administration role. Even with him as a senior adviser, though, Moderna and GSK lack immunity.

Lilly’s weight loss let-down is all about timing

30 Oct 2024

The obesity drug maker shed $50 bln of market value after sales disappointed the assumption that rising supply would meet endless demand. It may be a blip due to slow marketing. But a valuation triple industry norms leaves Eli Lilly no room to fumble its window to extract value.

Companies bear brunt of Britain’s fiscal trade-off

30 Oct 2024

New finance minister Rachel Reeves raised 40 bln pounds through higher levies, mostly on employers, to fund public services like health. She also changed debt rules to borrow more. It’s a bet that fiscal rectitude will help revive growth. But the ailing UK has few other options.

Philips’ China misery renews case for bold surgery

28 Oct 2024

The $25 bln Dutch medical group’s shares fell up to 17% after it said it would barely grow this year. Weak demand in its key Chinese market means any recovery is far off. The weak outlook makes it harder to justify keeping its sprawling consumer and healthcare divisions together.

CD&R $17 bln French deal may hinge on big retreat

15 Oct 2024

Paris is concerned about the future of critical medicines if the private equity firm buys a stake in Sanofi’s consumer unit. CD&R can promise bigger investment and still get a decent return. Giving up control by bringing in a Gallic co-investor might also soothe the government.

Sanofi sale is critical health check for mega LBOs

10 Oct 2024

The French pharma company is deciding whether to sell its consumer drugs unit to Clayton Dubilier & Rice or PAI for $17 bln, says Bloomberg. It helps that volatile equity markets make an alternative listing riskier. A successful deal could give large buyouts a shot in the arm.

Pfizer’s M&A disease brings activist cure

7 Oct 2024

The pharma giant generated over $30 bln of extra cash during the pandemic, then spent over twice as much on questionable deals. With shareholders sitting on a loss under CEO Albert Bourla, Starboard will push for a return to former CEO Ian Read’s parsimony.

CVS surgery would provide little if any relief

1 Oct 2024

As part of a strategic shakeup, the healthcare supermarket may try amputation. A $90 bln acquisition binge has left it indebted and worth less than $80 bln. The breakup math is flimsy, meaning the prescription for boss Karen Lynch is to stop buying and nurse the existing parts.

Copycat drugmakers will be low-key obesity winners

25 Sep 2024

Sandoz and other generic drugmakers are preparing to make cheap versions of Novo Nordisk’s weight-loss drugs. They could grab a large chunk of a potentially $150 bln market. Unlike the Danish group and peer Eli Lilly, their valuations do not yet reflect the potential opportunity.

Big Pharma lacks motive to prep for new pandemics

10 Sep 2024

The WHO warned the next outbreak may be 20 times more deadly than Covid-19. Moderna’s Corona surge should encourage drugmakers to build up vaccine units for the next virus. But with investors giving little credit for one-off jabs, there’s not much incentive to invest.

AIA loosens tight Chinese purse strings

22 Aug 2024

The $70 bln insurer reported a 25% increase in new business value in the first half, led by rapid growth in mainland China. Demand for the group's savings products is driving sales as the economy sputters. AIA's aggressive expansion onshore is paying off.

Mpox drugmaker’s shares may provide false comfort

16 Aug 2024

Bavarian Nordic, which makes a vaccine for the virus, gained $1 bln in value over the past week as the disease spread beyond Africa. The increase is equivalent to several million extra doses. That view, which implies a contained outbreak, may be too benign if mpox keeps mutating.